SCHEMBL6776971

SCHEMBL6776971

CCOC(=O)c1cn2c3c(cc(CN4CCOCC4)cc3c1=O)OC(c1ccccc1)C2

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.45
NPSR1 Q6W5P4 4/20 0.41
TSHR P16473 3/20 0.41
RXFP1 Q9HBX9 1/20 0.40
POLA1 P09884 1/20 0.40
LMNA P02545 4/20 0.39
MAPT P10636 3/20 0.39
GAA P10253 1/20 0.39
HTT P42858 1/20 0.39
HSD17B10 Q99714 3/20 0.39
KDM4E B2RXH2 1/20 0.39
HPGD P15428 1/20 0.39
MAPK1 P28482 1/20 0.38
STAT3 P40763 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
PARP1 P09874 1/20 0.38
LTA4H P09960 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6780790 0.88 RXFP1 (0.37) ALDH1A1NPSR1TSHRRXFP1POLA1
SCHEMBL6780920 0.87 RXFP1 (0.36) ALDH1A1NPSR1TSHRRXFP1POLA1
SCHEMBL6781920 0.83 ALDH1A1 (0.39) ALDH1A1NPSR1TSHRPOLA1LMNA
SCHEMBL6413852 0.82 ALDH1A1 (0.44) ALDH1A1TSHRPOLA1LMNAMAPT
SCHEMBL6779874 0.81 CNR2 (0.49) ALDH1A1NPSR1TSHRRXFP1LMNA
SCHEMBL6703845 0.80 POLA1 (0.62) ALDH1A1POLA1
SCHEMBL6780896 0.78 ALDH1A1 (0.43) ALDH1A1TSHRRXFP1POLA1LMNA
SCHEMBL6779854 0.75 CNR2 (0.47) ALDH1A1TSHRPOLA1LMNAMAPT
SCHEMBL6620430 0.74 POLA1 (0.65) ALDH1A1TSHRPOLA1LMNAMAPT
SCHEMBL6733387 0.74 POLA1 (0.44) ALDH1A1TSHRPOLA1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1299395-B1 OXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS UPJOHN CO (US) 2004-09-15 EP disclosed
US-6673793-B2 N-(4-CHLOROBENZYL)-9-(MORPHOLIN-4-YLMETHYL)-7-OXO-2-(S)-PYRIDIN-2-YL-2,3-DIHYDRO-7H-(1,4) OXAZINO(2,3,4-IJ)QUINOLINE-6-CARBOXAMIDE, FOR EXAMPLE; INHIBITING A VIRAL DNA POLYMERASE; TREATING VIRUSES OF HERPES FAMILY PHARMACIA & UPJOHN CO. 2004-01-06 US disclosed
EP-1299395-A1 OXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS PHARMACIA & UPJOHN COMPANY (US) 2003-04-09 EP disclosed
US-20020103170-A1 Oxazinoquinolones useful for the treatment of viral infections PHARMACIA & UPJOHN COMPANY 2002-08-01 US disclosed
WO-2002004462-A1 OXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS PHARMACIA & UPJOHN COMPANY (US) 2002-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020103170-A1 Oxazinoquinolones useful for the treatment of viral infections ZC3HAV1, RPL5, ZC3HAV1L ALDH1A1 594/4885NPSR1 4073/4885TSHR 4826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.